(APLS) Apellis Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03753U1060
APLS: EMPAVELI, SYFOVRE, APL-3007, Pegcetacoplan, Base Editing
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapies for diseases with significant unmet medical needs. The companys lead product, EMPAVELI (pegcetacoplan), is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic, and life-threatening blood disorder. Additionally, SYFOVRE (pegcetacoplan) is approved for geographic atrophy (GA), a leading cause of vision loss in older adults. The company is actively expanding EMPAVELIs indications to include C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function. It is also developing APL-3007, an siRNA targeting GA. Apellis has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the development and commercialization of pegcetacoplan and a partnership with Beam Therapeutics Inc. to leverage base editing technology for complement-driven diseases. Founded in 2009 and headquartered in Waltham, Massachusetts, the company has established itself as a leader in complement biology and innovative drug development.
Apellis Pharmaceuticals Inc. operates in the biotechnology sector, focusing on therapies for rare and serious diseases. Its product portfolio includes approved treatments for PNH and GA, with a robust pipeline addressing kidney, transplantation, and ophthalmic disorders. The companys collaborations highlight its commitment to innovation and strategic partnerships to advance its therapeutic pipeline.
Additional Sources for APLS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
APLS Stock Overview
| Market Cap in USD | 2,556m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2017-11-09 |
APLS Stock Ratings
| Growth Rating | -46.9 |
| Fundamental | -27.8 |
| Dividend Rating | 0.0 |
| Rel. Strength | -52 |
| Analysts | 4.14/5 |
| Fair Price Momentum | 14.21 USD |
| Fair Price DCF | - |
APLS Dividends
No Dividends PaidAPLS Growth Ratios
| Growth Correlation 3m | -93.9% |
| Growth Correlation 12m | -88.4% |
| Growth Correlation 5y | -9.1% |
| CAGR 5y | -11.54% |
| CAGR/Max DD 5y | -0.14 |
| Sharpe Ratio 12m | -1.02 |
| Alpha | -68.17 |
| Beta | 0.943 |
| Volatility | 71.76% |
| Current Volume | 2998.6k |
| Average Volume 20d | 2538.3k |
As of May 09, 2025, the stock is trading at USD 17.81 with a total of 2,998,641 shares traded.
Over the past week, the price has changed by -11.30%, over one month by -4.76%, over three months by -37.90% and over the past year by -57.90%.
Probably not. Based on ValueRay Fundamental Analyses, Apellis Pharmaceuticals (NASDAQ:APLS) is currently (May 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -27.76 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of APLS as of May 2025 is 14.21. This means that APLS is currently overvalued and has a potential downside of -20.21%.
Apellis Pharmaceuticals has received a consensus analysts rating of 4.14. Therefor, it is recommend to buy APLS.
- Strong Buy: 11
- Buy: 3
- Hold: 8
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, APLS Apellis Pharmaceuticals will be worth about 15.8 in May 2026. The stock is currently trading at 17.81. This means that the stock has a potential downside of -11.06%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 41.5 | 133% |
| Analysts Target Price | 41.5 | 133% |
| ValueRay Target Price | 15.8 | -11.1% |